WO2014045425A1 - Blood sugar management system - Google Patents

Description

Blood glucose management system

The present invention relates to a blood glucose management system and a blood glucose management method for continuously injecting insulin subcutaneously into an injection target.

Recently, insulin pumps for injecting insulin into the body of diabetic patients (subjects) have been developed. By using this pump, insulin is continuously and intermittently supplied into the patient's body without injection, so that the blood sugar level can be easily adjusted. Various techniques for realizing appropriate blood glucose management while further reducing the burden on the patient have been proposed.

In Japanese Patent Application Laid-Open No. 2004-024699, blood glucose level data measured from a patient is supplied to a management server connected to a mobile communication network, and an insulin injection amount is determined using the management server. There have been proposed systems and methods for reflecting the injection amount on the injection device to be mounted.

By the way, when the symptom progresses rapidly after hypoglycemia occurs, the patient may cause serious symptoms such as loss of consciousness. At this time, the patient cannot request the emergency to the surroundings, but it is necessary to take some measures and measures for the patient.

However, the system described in Japanese Patent Application Laid-Open No. 2004-024699 is originally intended for daily blood glucose management, and no consideration is given to such an emergency situation.

The present invention has been made to solve the above-described problems, and it is an object of the present invention to provide a blood sugar management system and a blood sugar management method capable of executing an effective treatment or the like on an injection target.

The blood glucose management system according to the present invention includes a pump device that continuously injects insulin subcutaneously into an injecting body, a pump device that has a control unit that controls the insulin injecting operation by the pump, and the injecting body A vital sensor for obtaining a vital sign indicating a vital sign of the subject, and a hypoglycemia judgment means for judging whether or not the injected body has a sign of hypoglycemia based on the vital sign signal obtained from the vital sensor The pump device from the normal mode in which the insulin is injected according to the injecting protocol instructed when the hypoglycemia determining means determines that there is a sign of the hypoglycemia. It further has a mode switching section for switching to a hypoglycemia mode for performing an emergency treatment or measure against the above.

Thus, when it is determined that there is a sign of hypoglycemia by the hypoglycemia determination means, an emergency treatment or measure for hypoglycemia is performed from the normal mode in which insulin is injected according to the instructed injection protocol. Since a mode switching unit for switching to hypoglycemia mode is provided, it is possible to perform emergency treatment or measures on the injected body with signs of hypoglycemia and perform effective treatment etc. it can.

In addition, it is preferable that the control unit controls the pump so that the insulin injection is reduced or stopped when the mode switching unit switches to the hypoglycemia mode. Thereby, the treatment which considered the risk that the symptom of a to-be-injected body gets worse by excessive supply of insulin can be taken.

In addition, the pump device further includes notification means for notifying a user, and the control unit notifies that there is an indication of the hypoglycemia when the mode switching unit is switched to the hypoglycemia mode. It is preferable to control the notification means. Thereby, instead of an injectable body that cannot move due to loss of consciousness or the like, it is possible to take measures to help notify others of the presence of the injectable body.

Furthermore, the vital sensor is preferably composed of at least one of a pulse sensor, an activity sensor, a sweat sensor, an acceleration sensor, and a blood glucose sensor.

Furthermore, the vital sensor includes a pulse sensor that acquires a pulse rate as the biological signal, and an activity amount sensor that acquires an activity amount as the biological signal, and the hypoglycemia determination means has the pulse rate It is preferable to determine that there is a sign of the hypoglycemia when the activity amount is equal to or greater than the first threshold value and the activity amount is equal to or less than the second threshold value.

Alternatively, the vital sensor is configured by a sweat sensor that acquires a sweat amount as the biological signal, and the hypoglycemia determination means has an indication of the hypoglycemia when the sweat amount is equal to or greater than a threshold value. It is preferable to discriminate.

Alternatively, the vital sensor is configured by an acceleration sensor that acquires a time series of acceleration as the biological signal, and the hypoglycemia determination means is configured such that the main frequency in the time series spectrum of the acceleration is equal to or greater than a threshold value. It is preferable to determine that there is a sign of hypoglycemia.

Alternatively, the vital sensor is configured with a blood glucose sensor that acquires a blood glucose level as the biological signal, and the hypoglycemia determination means has an indication of the hypoglycemia when the blood glucose level is equal to or higher than a threshold value. It is preferable to discriminate.

A blood glucose management method according to the present invention is a method using a pump device having a pump for continuously injecting insulin subcutaneously into an injected body, and using a vital sensor, the vital sign of the injected body is determined. An acquisition step of acquiring a biological signal to be shown, a determination step of determining whether or not the injected body has a sign of hypoglycemia based on the acquired biological signal, and a sign of the hypoglycemia A switching step of switching from a normal mode in which the insulin is injected via the pump according to an instructed infusion protocol to a hypoglycemia mode in which an emergency treatment or measure for the hypoglycemia is performed when determined. It is characterized by that.

According to the blood sugar management system and the blood sugar management method according to the present invention, when it is determined that there is a sign of hypoglycemia, the emergency mode for hypoglycemia is changed from the normal mode in which insulin is injected according to the instructed injection protocol. Since the mode is switched to the hypoglycemia mode in which treatment or measures are performed, it becomes possible to perform emergency treatment or measures on an injected body in which signs of hypoglycemia are seen, and effective treatments can be performed. .

1 is a schematic perspective view of a blood sugar management system according to this embodiment. It is an electrical block diagram of the pump device shown in FIG. FIG. 3A is a schematic perspective view of a vital sensor. FIG. 3B is a schematic block diagram showing a configuration of the vital sensor of FIG. 3A. It is a graph which shows an example of a time-dependent change of the vital sign in a to-be-injected body. It is a flowchart with which operation | movement description of the pump device in normal mode is provided. It is a graph which shows the 1st example of a time-dependent change of vital sign. It is a graph which shows the 2nd example of a time-dependent change of vital sign. It is a flowchart provided for operation | movement description of the pump device in a hypoglycemia mode. It is a schematic block diagram of the blood glucose management system which concerns on a 1st modification.

Hereinafter, a blood glucose management method according to the present invention will be described with reference to the accompanying drawings by citing preferred embodiments in relation to a blood glucose management system.

[Configuration of Blood Sugar Management System 10]
<Overall configuration>
FIG. 1 is a schematic perspective view of a blood sugar management system 10 according to this embodiment.

The blood glucose management system 10 basically acquires a pump device 12 for continuously injecting insulin subcutaneously into an injected body including a diabetic patient, and a biological signal indicating a vital sign of the injected body. And a vital sensor 14.

The pump device 12 has a substantially rectangular casing 16. On the main surface 18, a display unit 20 (notification unit) that displays various images that visualize the operation state of the pump device 12 and an operation unit 22 including a plurality of push buttons are arranged.

The short side edge of the side surface 24 of the housing 16 is cut away, whereby an insertion port 26 is formed. Through this insertion port 26, a substantially cylindrical insulin pump 28 (pump) can be accommodated in the casing 16 and can be detached from the casing 16. One end 32 of a tube 30 for transferring insulin is connected to the tip of the insulin pump 28. The other end 34 of the tube 30 is provided with a fitting portion 36 and can be fitted to a part of the injection set 38 (a fitting portion 44 described later).

The infusion set 38 includes a disk-shaped fixed sheet 40, a cannula 42 disposed substantially at the center of one surface 41 side of the fixed sheet 40, and a fitted portion 44 disposed on the other surface 43 of the fixed sheet 40. The An adhesive layer is provided on one surface 41 of the fixing sheet 40. An opening 46 is provided on the upper surface side of the fitted portion 44, and communicates with the inside of the cannula 42 through the opening 46.

Hereinafter, the insulin injection operation will be described. First, after the cannula 42 is punctured on the body surface of the body to be injected, the infusion set 38 is fixed to the skin by bringing one surface 41 (adhesive layer) of the fixing sheet 40 into contact with the skin. Thereby, the cannula 42 can be placed under the skin. Then, by fitting the fitting portion 36 of the tube 30 to the fitted portion 44 of the infusion set 38, the inside of the insulin pump 28 is connected to the outside 48 via the tube 30, the fitted portion 44 and the cannula 42. Communicate. That is, insulin pushed out from the insulin pump 28 is transferred to the outside 48 through the tube 30, the fitted portion 44 and the cannula 42, and as a result, injected into the inside of the injected body. By successively repeating this transfer operation, insulin can be continuously or intermittently injected subcutaneously into the injection target.

FIG. 2 is an electrical block diagram of the pump device 12 shown in FIG.

The pump device 12 includes a display unit 20, an operation unit 22, and an insulin pump 28 in FIG. 1, a central processing unit (hereinafter referred to as CPU 50), a memory 52, a communication module 54, and an audio output unit 56 (notification means). ).

The communication module 54 transmits and receives various signals to and from an external device by wire or wireless. As the communication module 54, for example, a radio frequency (RF) module for realizing wireless communication may be applied. In particular, since the pump device 12 and the vital sensor 14 are mounted on the same injection target, standards for near field communication (for example, a body area network defined in “IEEE802.15.6”) may be applied. .

The sound output unit 56 outputs various sounds for informing the user. The voice output unit 56 outputs, for example, a warning sound including a buzzer and a beep, and a guidance message in each language.

The memory 52 stores programs and data necessary for the CPU 50 to control each component. The memory 52 may be a non-transitory storage medium including a non-volatile memory and a hard disk. In this example, injection protocol data 66 and a plurality of discrimination condition data 68 are stored.

The CPU 50 can implement the functions of the control unit 58, the hypoglycemia determination unit 60 (hypoglycemia determination unit), the mode switching unit 62, and the notification instruction unit 64 by reading and executing the program stored in the memory 52. It is.

<Configuration of vital sensor 14>
3A is a schematic perspective view of the vital sensor 14, and FIG. 3B is a schematic block diagram showing a configuration of the vital sensor 14 of FIG. 3A. In the illustrated example, a multipurpose measuring instrument which is one form of the vital sensor 14 is illustrated.

As shown in FIG. 3A, the vital sensor 14 fixed to a part of the band 70 is attached to the distal end portion (more specifically, the wrist 74) of the arm 72 of the injection target.

The vital sensor 14 shown in FIG. 3B basically includes a CPU 80, a memory 81, a communication module 82, a pulse sensor 83, an activity sensor 84, an operation unit 85, and a display unit 86. Since the CPU 80, the memory 81, the communication module 82, the operation unit 85, and the display unit 86 can have the same configuration as that in FIG. 2, description of the configuration and function of each unit is omitted.

The pulse sensor 83 is a sensor that can acquire a pulse rate as a biological signal by detecting a pulsation (pressure) appearing on the skin. The pulse sensor 83 is not limited to this method, and may employ various detection methods such as an optical sensor that detects a change in blood flow from the amount of reflected infrared light projected toward the skin (capillary blood vessel).

The activity amount sensor 84 includes, for example, a triaxial acceleration sensor, and acquires the activity amount as a biological signal by converting the detected acceleration into a work amount. Examples of the amount of activity include energy consumption, METs (metabolic equivalents) values, exercise values, and the like.

Referring back to FIG. 3A, a display unit 86 as a notification unit is provided on one surface 76 of the vital sensor 14 that does not contact the injection target. On the other hand, the position of the other surface 78 of the vital sensor 14 is adjusted so as to come into pressure contact with a position close to the artery inside the wrist 74.

<Relationship between hypoglycemia and various vital signs>
FIG. 4 is a graph showing an example of a temporal change of vital signs in the injectable body. The horizontal axis of the graph represents time (time), and the vertical axis represents blood glucose level (unit: mg / dl) and pulse rate (unit: BPM) as vital signs. In the example of this figure, the change when the to-be-injected body which was in the normal state suddenly developed hypoglycemia is shown.

When the blood glucose level is 70 [mg / dl] or higher, the pulse rate changes stably. Thereafter, when hypoglycemia develops and the blood glucose level falls below 70 [mg / dl], the parasympathetic nerve becomes active and bradycardia occurs, so the pulse rate temporarily decreases. Then, symptoms such as a feeling of hunger and lack of illness occur in the injected body, and symptoms such as headache, dizziness, and nausea occur when further progressed.

After that, when the blood glucose level falls below 50 [mg / dl], in order to maintain life, a large amount of hormones such as adrenaline that increases blood glucose are secreted. As a result, the stimulated sympathetic nerve becomes active and tachycardia occurs, and the pulse rate rapidly increases. At this time, symptoms such as sweating, palpitation, or tremor occur. Thus, changes over time in various vital signs of the injected body can be a material for determining whether or not hypoglycemia has developed.

[Operation of Blood Sugar Management System 10]
Next, the operation of the blood glucose management system 10 will be described with reference to the flowcharts of FIGS. 5 and 8 and necessary drawings. In this embodiment, two types of operation modes related to the pump device 12, specifically, “normal mode” and “hypoglycemia mode” are prepared, and mode switching is performed in a timely manner. The operation mode of the pump device 12 when there is no sign (trend) of hypoglycemia is referred to as “normal mode”. The operation mode of the pump device 12 when there is a sign of hypoglycemia is referred to as “hypoglycemia mode”.

<Description of normal mode operation>
First, the operation of the pump device 12 in the normal mode will be described in detail with reference to the flowchart of FIG. Note that in the normal mode, the pump device 12 performs the operation of injecting insulin according to the commanded infusion protocol (initial infusion volume, infusion rate, total infusion volume, etc.).

In step S1, the control unit 58 instructs the insulin pump 28 to inject insulin. Specifically, the control unit 58 refers to the injection protocol data 66 read from the memory 52 and transmits a control signal indicating the amount of insulin injected. Thereby, as shown in FIG. 1, a predetermined injection amount of insulin is injected into the injected body through the tube 30 and the cannula 42.

In step S2, the control unit 58 acquires a biological signal from the vital sensor 14. Prior to the acquisition, the pulse sensor 83 and the activity amount sensor 84 acquire the pulse rate and the activity amount of the injected body, respectively, in accordance with a command from the CPU 80 in FIG. 3B. Thereafter, the communication module 82 sends out the pulse rate and activity as a biological signal. Thereafter, the CPU 50 of FIG. 2 temporarily stores the biological signal received via the communication module 54 in the memory 52. This acquisition process may be executed at a sampling interval preset in the vital sensor 14, or may be executed in response to a request (measurement instruction) from the pump device 12.

In step S3, the hypoglycemia determination unit 60 determines whether or not there is a sign of hypoglycemia in the injected body based on the biological signal acquired in step S2. Here, using the pulse rate and the amount of activity as vital signs, the presence / absence of the signs is determined in a complex and multifaceted manner. Specifically, the hypoglycemia determination unit 60 is low when the pulse rate is equal to or greater than a first threshold (for example, 75 [BPM]) and the amount of activity is equal to or less than the second threshold (for example, Ath). Determine if there is any sign of glycemia.

6 and 7 are graphs showing examples of changes in vital signs over time. FIG. 6 is a graph illustrating changes in pulse rate and amount of activity when the injected body starts exercising. FIG. 7 is a graph illustrating changes in the pulse rate and the amount of activity when the injected body develops hypoglycemia.

In FIG. 6, the pulse rate is smaller than the first threshold when time t <T, but the pulse rate is larger than the first threshold when time t> T. On the other hand, in the case of time t> T, the activity amount is larger than the second threshold value. In this case, the hypoglycemia determination unit 60 estimates that the pulse rate has increased due to exercise, and determines that there is no sign of hypoglycemia.

In FIG. 7, the pulse rate is smaller than the first threshold when time t <T, but the pulse rate is larger than the first threshold when time t> T. In the case of time t> T, the amount of activity is smaller than the second threshold value. In this case, the hypoglycemia determination unit 60 excludes the possibility that the pulse rate has increased due to exercise, and determines that there is a sign of hypoglycemia.

In this way, the hypoglycemia determination unit 60 sequentially determines whether or not there is a sign of hypoglycemia in the injected body (step S4). If it is determined that there is no sign, the process returns to step S1 and steps S1 to S3 are sequentially repeated. On the other hand, when it is determined that there is an indication, the mode switching unit 62 notifies the control unit 58 that the “normal mode” is switched to the “hypoglycemia mode”.

<Operation description of hypoglycemia mode>
Second, the operation of the pump device 12 in the hypoglycemia mode will be described in detail with reference to the flowchart of FIG. It should be noted that in the hypoglycemia mode, the pump device 12 performs a processing operation (hereinafter referred to as “emergency processing”) for performing an emergency treatment or measure for hypoglycemia.

In step S5, the control unit 58 instructs each unit of the pump device 12 to execute the emergency process. Here, it is assumed that the injected body has lost consciousness as a result of the rapid progression of hypoglycemia.

As a first form of the treatment operation, the control unit 58 may instruct the insulin pump 28 to reduce the amount of insulin injected compared to the normal mode. As a second form of treatment operation, the controller 58 may instruct the insulin pump 28 to stop injecting insulin. These are treatments that take into account the risk that the symptoms of the injected body will worsen due to an excessive supply of insulin.

As a first form of the action operation, the control unit 58 may instruct the audio output unit 56 to output various sounds for notifying the user that there is a sign of hypoglycemia. As a second form of the action operation, the control unit 58 may instruct the display unit 20 to display various images for notifying the user that there is a sign of hypoglycemia. As a third form of the action operation, the control unit 58 transmits an instruction signal to the vital sensor 14 mounted at a position where it can be easily seen, and notifies that there is a sign of hypoglycemia on behalf of the pump device 12. Also good. These are measures for helping other people to know the existence of the injected body instead of the injected body that cannot move due to loss of consciousness or the like. In particular, it is possible to prevent misunderstanding that the injection target is sleeping by another person by performing a notification reminiscent of an emergency situation.

In step S6, the control unit 58 starts monitoring the elapsed time from when the emergency process in step S5 is executed (that is, initializes the timer).

In step S <b> 7, the control unit 58 acquires a biological signal from the vital sensor 14. This acquisition process may be the same as or different from the case of step S2.

In step S8, the hypoglycemia determination unit 60 determines whether or not there is a sign of hypoglycemia in the injected body based on the biological signal acquired in step S7. In this determination processing, the same or different method as in step S3 may be used.

In step S9, the hypoglycemia determination unit 60 determines whether or not the injection target has recovered from the hypoglycemia. The hypoglycemia determination unit 60 may perform the determination after considering not only the current determination result but also the most recent determination result at least once. If it is determined that it has not been recovered, the process proceeds to the next step (S10).

In step S10, the control unit 58 determines whether or not a certain time has elapsed since the start of monitoring in step S6. If it is determined that the time has not elapsed, the process returns to step S7, and steps S7 to S9 are sequentially repeated. On the other hand, if it is determined that the time has elapsed, the process returns to step S5 (emergency process), and steps S5 to S10 are sequentially repeated.

If it is determined in step S9 that the patient has recovered from hypoglycemia, in step S11, the control unit 58 ends the emergency process in step S5 and the time monitoring in step S6. Thereafter, the mode switching unit 62 notifies the control unit 58 of switching from the “hypoglycemia mode” to the “normal mode”.

As described above, the blood glucose management system 10 is operated while switching between the “normal mode” and the “hypoglycemia mode” in a timely manner.

[Effect of the present invention]
The blood glucose management system 10 includes an insulin pump 28 that continuously injects insulin subcutaneously into an injected body, a pump device 12 that has a control unit 58 that controls an insulin injecting operation, and a vital sign of the injected body. And a hypoglycemia determination unit 60 for determining whether or not the injected body has a sign of hypoglycemia based on the acquired biological signal.

Then, when it is determined by the hypoglycemia determining unit 60 that there is a sign of hypoglycemia, an emergency treatment for hypoglycemia is performed from the “normal mode” in which insulin is injected in accordance with the instructed injection protocol data 66. Since the mode switching unit 62 for switching to the “hypoglycemia mode” for performing the measure is provided, it becomes possible to perform an emergency treatment or measure on the injected body in which signs of hypoglycemia are observed, Can be implemented.

[First Modification]
FIG. 9 is a schematic configuration diagram of a blood sugar management system 10A according to the first modification.

The blood glucose management system 10 </ b> A further includes a data processing device 90 in addition to the pump device 12 </ b> A and the vital sensor 14. Here, the pump device 12A is substantially the same as the configuration shown in FIGS. 1 and 2 except that the function of the hypoglycemia determination unit 60 (see FIG. 2) is missing. The data processing device 90 includes the hypoglycemia determination unit 60 and is configured to be able to communicate with the pump device 12A and the vital sensor 14.

Even when this configuration is adopted, the flowcharts shown in FIGS. 5 and 8 can be executed. For example, the data processing device 90 acquires a biological signal from the vital sensor 14 (see steps S2 and S7), performs a hypoglycemia discrimination process (see steps S3 and S8), and pumps the discrimination result. What is necessary is just to supply to the device 12A side. Thus, even if the hypoglycemia determination means is provided separately from the pump device 12A, the same effect as the present invention can be obtained.

[Second Modification]
The vital sensor 14 may be composed of, for example, at least one of a pulse sensor, an activity sensor, a sweat sensor, an acceleration sensor, and a blood glucose sensor. In this case, the determination condition data 68 corresponding to the type (or combination) of the vital sensor 14 may be stored in the memory 52 and selectively read out as necessary.

<Sweating sensor>
The vital sensor 14 may be a sweat sensor that acquires the amount of sweat as a biological signal. In this case, the hypoglycemia determination unit 60 determines that there is a sign of hypoglycemia when the amount of sweat is equal to or greater than the threshold. This is because when the blood glucose level falls below 50 [mg / dl], the sympathetic nerve becomes active, so that the symptom of sweating (especially cold sweat) is likely to occur. It is desirable that the body to be injected is equipped with a perspiration sensor at a site (palm or sole of the foot) where cold sweat is easily detected. As the perspiration sensor, for example, various methods including a ventilation capsule type (difference method and flow rate compensation method) can be adopted.

<Acceleration sensor>
The vital sensor 14 may be configured by an acceleration sensor that acquires a time series of acceleration as a biological signal. In this case, the hypoglycemia determination unit 60 determines that there is a sign of hypoglycemia when the main frequency in the time-series spectrum of acceleration is equal to or greater than the threshold value. This is because when the blood sugar level falls below 50 [mg / dl], the sympathetic nerves become active, so that the symptoms of trembling are likely to occur. As the acceleration sensor, various types including a piezoelectric type, a capacitance type, a servo type, and a bubble type can be adopted.

<Blood glucose sensor>
The vital sensor 14 may be a blood glucose sensor that acquires a blood glucose level as a biological signal. In this case, the hypoglycemia determination unit 60 determines that there is a sign of hypoglycemia when the blood glucose level is equal to or higher than the threshold value. Although most preferable in terms of directly monitoring the change in blood glucose level, it is known that there are individual differences in this threshold value (judgment criterion). Therefore, the accuracy of the discrimination process is further improved by using other types of vital sensors together. As a blood glucose sensor, a sensor that optically measures glucose in blood and a sensor that measures blood glucose level electrically (electrochemical method) by an enzyme electrode method using an enzyme such as glucose oxidase (GOD) are applied. Also good.

It should be noted that the present invention is not limited to the above-described embodiment, and it is needless to say that the present invention can be freely changed without departing from the gist of the present invention.

Claims (8)

A pump device (12, 12A) having a pump (28) for continuously injecting insulin subcutaneously into an injecting body and a control unit (58) for controlling the infusion operation of the insulin by the pump (28); ,
A vital sensor (14) for obtaining a biological signal indicating a vital sign of the injection target;
Hypoglycemia determination means (60) for determining whether or not the injected body has a sign of hypoglycemia based on the biological signal acquired from the vital sensor (14),
The pump device (12, 12A)
From the normal mode in which the insulin is injected according to the instructed injection protocol (66) when the hypoglycemia determination means (60) determines that there is a sign of the hypoglycemia, the emergency for the hypoglycemia is provided. A blood glucose management system (10, 10A) further comprising a mode switching unit (62) for switching to a hypoglycemia mode for performing various treatments or measures. The system (10, 10A) according to claim 1,
The control unit (58) controls the pump (28) to reduce or stop the infusion of insulin when the mode switching unit (62) switches to the hypoglycemia mode. A blood glucose management system (10, 10A). The system (10, 10A) according to claim 1,
The pump device (12, 12A) further includes notification means (20, 56) for notifying the user,
When the control unit (58) is switched to the hypoglycemia mode by the mode switching unit (62), the control unit (58) notifies the informing means (20, 56) that there is an indication of the hypoglycemia. A blood glucose management system (10, 10A) characterized by controlling. The system (10, 10A) according to any one of claims 1 to 3,
The blood glucose management system (10, 10A), wherein the vital sensor (14) includes at least one of a pulse sensor, an activity sensor, a sweat sensor, an acceleration sensor, and a blood glucose sensor. The system (10, 10A) according to claim 4,
The vital sensor (14) includes a pulse sensor that acquires a pulse rate as the biological signal, and an activity amount sensor that acquires an activity amount as the biological signal.
The hypoglycemia determination means (60) determines that there is an indication of the hypoglycemia when the pulse rate is equal to or higher than a first threshold and the amount of activity is equal to or lower than a second threshold. Blood glucose management system (10, 10A). The system (10, 10A) according to claim 4,
The vital sensor (14) is composed of a perspiration sensor that acquires a perspiration amount as the biological signal,
The blood glucose management system (10, 10A), wherein the hypoglycemia discrimination means (60) discriminates that there is an indication of the hypoglycemia when the amount of sweating is not less than a threshold value. The system (10, 10A) according to claim 4,
The vital sensor (14) is composed of an acceleration sensor that acquires a time series of acceleration as the biological signal,
The hypoglycemia determination means (60) determines that there is a sign of the hypoglycemia when a main frequency in the time-series spectrum of the acceleration is equal to or higher than a threshold value. 10A). The system (10, 10A) according to claim 4,
The vital sensor (14) includes a blood glucose sensor that acquires a blood glucose level as the biological signal,
The blood glucose management system (10, 10A), wherein the hypoglycemia determination means (60) determines that there is an indication of the hypoglycemia when the blood glucose level is equal to or higher than a threshold value.

Images